PFIZER BUPIVACAINE 0.5% w/v WITH ADRENALINE (epinephrine) 1:200,000 injection solution vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer bupivacaine 0.5% w/v with adrenaline (epinephrine) 1:200,000 injection solution vial

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 5.27 mg/ml (equivalent: bupivacaine hydrochloride, qty 5 mg/ml); adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium metabisulfite; citric acid; sodium citrate - pfizer bupivacaine with adrenaline injection is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows;,surgical anaesthesia:,- epidural block for surgery,- field block (minor and major nerve blocks and infiltration),analgesia,- continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,- field block (minor nerve block and infiltration),the choice of 2 strengths, 0.25%, and 0.5% makes it possible to vary the degree of motor blockade.

PFIZER BUPIVACAINE 0.25% w/v WITH ADRENALINE (epinephrine) 1:400,000 injection solution vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer bupivacaine 0.25% w/v with adrenaline (epinephrine) 1:400,000 injection solution vial

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 2.64 mg/ml (equivalent: bupivacaine hydrochloride, qty 2.5 mg/ml); adrenaline (epinephrine) acid tartrate, quantity: 4.5 microgram/ml (equivalent: adrenaline (epinephrine), qty 2.5 microgram/ml) - injection, solution - excipient ingredients: sodium citrate; citric acid; sodium metabisulfite; water for injections; sodium chloride - pfizer bupivacaine with adrenaline is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows;,surgical anaesthesia:,- epidural block for surgery,- field block (minor and major nerve blocks and infiltration),analgesia,- continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,- field block (minor nerve block and infiltration),the choice of 2 strengths, 0.25%, and 0.5% makes it possible to vary the degree of motor blockade.

Pfizer (Australia) SODIUM CHLORIDE 0.9% (900mg/100mL) IV infusion Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (australia) sodium chloride 0.9% (900mg/100ml) iv infusion

pfizer australia pty ltd - sodium chloride, quantity: 900 mg - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Pfizer (Australia) SODIUM CHLORIDE 0.9% (450mg/50mL) intravenous infusion Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (australia) sodium chloride 0.9% (450mg/50ml) intravenous infusion

pfizer australia pty ltd - sodium chloride, quantity: 450 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Pfizer (Australia) SODIUM BICARBONATE 8.4% (8.4 g/100 mL) injection BP vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (australia) sodium bicarbonate 8.4% (8.4 g/100 ml) injection bp vial

pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.